Publications by authors named "D Solmaz"
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the north-south gradient hypothesis, suggesting that individuals with rheumatoid arthritis (RA) in southern regions (like Turkey) tend to have a younger age of onset and milder disease than those in northern regions (like Denmark).
- In a comparison of 223 treatment-naïve RA patients from Denmark and Turkey, it was found that Danish patients had a later onset age (60 years) and more severe joint symptoms compared to Turkish patients (51 years).
- The findings support the hypothesis and reveal that Danish patients have more genetic risk factors for RA, prompting the need for future research into the genetic and environmental influences on these regional differences.
Objectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort.
Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria.
Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA).
Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA).
Article Synopsis
- The study focuses on translating the Measure of Activity Performance of the Hand (MAP-Hand) into Turkish and assessing its effectiveness for those with rheumatoid arthritis (RA).
- The translated MAP-Hand was pilot tested on 30 participants and later administered to 185 adults, collecting various physical and health-related data.
- Results indicated that the Turkish MAP-Hand is reliable and valid, showing high internal consistency and strong correlations with disease activity, pain levels, and hand strength, proving its usefulness in evaluating hand function.